Scarica l'app Stockscreener
2.00
10.19%
0.185
Pre-mercato:
1.97
-0.03
-1.50%
Windtree Therapeutics Inc Borsa (WINT) Ultime notizie
FY2024 Earnings Forecast for WINT Issued By Zacks Small Cap - Defense World
Windtree Therapeutics Secures Patent for Istaroxime IV Formulation in Acute Heart Failure - MSN
Windtree (WINT) Sees Pre-Market Surge Following Key Patent Milestone - Stocks Telegraph
SponsoredImpartialComprehensive - Research Tree
Windtree Therapeutics (WINT) Shares Are Volatile: What's Going On? - Benzinga
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage - Yahoo Finance
WINTWindtree Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Windtree's Heart Failure Treatment Gains Critical Patent ProtectionWhat This Means for AHF Patients - StockTitan
Windtree Therapeutics Files Patent Application in India for Istaroxime, Advancing Arrhythmia Treatment - MSN
Discovery Laboratories Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015 - Marketscreener.com
Comparing Senti Biosciences (NASDAQ:SNTI) and Windtree Therapeutics (NASDAQ:WINT) - Defense World
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Drop in Short Interest - Defense World
Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India - The Manila Times
Windtree's Cardiac Drug Patent Filing Targets India's Massive MarketPhase 3 Trials on Horizon - StockTitan
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
Windtree Therapeutics, Inc. Announces Reverse Stock Split - GlobeNewswire
Windtree Therapeutics approves 1-for-50 reverse stock split - MSN
Windtree Therapeutics Approves 1-for-50 Reverse Stock Split; Shares Fall Pre-Bell -February 18, 2025 at 09:35 am EST - Marketscreener.com
Windtree Therapeutics Announces Reverse Stock Split Approval - TipRanks
Windtree Therapeutics approves 1-for-50 reverse stock split By Investing.com - Investing.com South Africa
Strategic 1:50 Reverse Split: Windtree's Bold Move to Secure Nasdaq Future - StockTitan
Windtree Therapeutics Highlights Promising Phase 2b Results for Istaroxime - MSN
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Drop in Short Interest - Defense World
Windtree reports positive Phase 2b study on heart failure therapy - MSN
Windtree reports positive Phase 2b study on heart failure therapy By Investing.com - Investing.com South Africa
Windtree Announces Special Late-Breaking Clinical Science - GlobeNewswire
Breakthrough Heart Failure Drug Shows Remarkable Safety Profile in Latest Clinical Trial - StockTitan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
The -95.92% Simple Moving Average of Windtree Therapeutics Inc’s (WINT) Stock in the Past 200 Days - The News Heater
Market Watch Highlights: Windtree Therapeutics Inc (WINT) Ends on an Downturn Note at 0.12 - The Dwinnex
Windtree Therapeutics Inc (NASDAQ: WINT) Stock Dropped -60.95% Over A Month – Any Room To Run? - Marketing Sentinel
Windtree Therapeutics enacts reverse stock split, expands equity plan - MSN
WINT: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
WINT (Windtree Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
It makes sense and dollars to buy Windtree Therapeutics Inc (WINT) stock - SETE News
Windtree Therapeutics enacts reverse stock split, expands equity plan By Investing.com - Investing.com Australia
This morning’s top pick is Windtree Therapeutics Inc (NASDAQ:WINT) - US Post News
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 72.4% - Defense World
Windtree Therapeutics adjusts Series C Preferred Stock terms - MSN
What Did We Find About Insider Trading At Windtree Therapeutics Inc (NASDAQ: WINT)? - Stocks Register
Windtree Therapeutics Announces Offer to Reduce Conversion Price of Series C Preferred Stock - Defense World
2.14%
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):